Brice Ozenne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2247942/publications.pdf

Version: 2024-02-01

394421 315739 1,816 56 19 38 citations h-index g-index papers 62 62 62 2602 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer's disease in hypertension. Brain, 2023, 146, 1141-1151.	7.6	30
2	Efficient Estimation in the Fine and Gray Model. Journal of the American Statistical Association, 2023, 118, 2482-2490.	3.1	2
3	Controlling the familywise error rate when performing multiple comparisons in a linear latent variable model. Computational Statistics, 2023, 38, 1-23.	1.5	2
4	The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study. Frontiers in Endocrinology, 2022, 13, 799675.	3.5	5
5	Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. Frontiers in Pharmacology, 2022, 13, 841648.	3.5	29
6	Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study. Journal of Psychopharmacology, 2022, 36, 626-636.	4.0	11
7	Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study. Translational Psychiatry, 2022, 12, .	4.8	7
8	Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. Journal of Psychopharmacology, 2021, 35, 459-468.	4.0	40
9	Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig. European Neuropsychopharmacology, 2021, 42, 1-11.	0.7	19
10	Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study. Statistics in Medicine, 2021, 40, 553-565.	1.6	5
11	A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons. Biometrical Journal, 2021, 63, 272-288.	1.0	4
12	A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. International Journal of Molecular Sciences, 2021, 22, 835.	4.1	96
13	Correcting the bias of the net benefit estimator due to rightâ€eensored observations. Biometrical Journal, 2021, 63, 893-906.	1.0	3
14	Reward processing in major depressive disorder and prediction of treatment response – Neuropharm study. European Neuropsychopharmacology, 2021, 44, 23-33.	0.7	10
15	Default mode network functional connectivity negatively associated with trait openness to experience. Social Cognitive and Affective Neuroscience, 2021, 16, 950-961.	3.0	12
16	Pretreatment qEEG biomarkers for predicting pharmacological treatment outcome in major depressive disorder: Independent validation from the NeuroPharm study. European Neuropsychopharmacology, 2021, 49, 101-112.	0.7	18
17	NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD. Journal of Psychiatric Research, 2021, 141, 57-65.	3.1	12
18	Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. European Neuropsychopharmacology, 2021, 50, 121-132.	0.7	57

#	Article	IF	Citations
19	The asymptotic distribution of the Net Benefit estimator in presence of right-censoring. Statistical Methods in Medical Research, 2021, 30, 2399-2412.	1.5	4
20	Stress-Hormone Dynamics and Working Memory in Healthy Women Who Use Oral Contraceptives Versus Non-Users. Frontiers in Endocrinology, 2021, 12, 731994.	3.5	9
21	Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial. BMJ Open, 2021, 11, e052922.	1.9	1
22	The structure of the serotonin system: A PET imaging study. NeuroImage, 2020, 205, 116240.	4.2	17
23	Common <scp><i>HTR2A</i></scp> variants and <scp>5â€HTTLPR</scp> are not associated with human in vivo serotonin <scp>2A</scp> receptor levels. Human Brain Mapping, 2020, 41, 4518-4528.	3.6	19
24	Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol. Frontiers in Psychiatry, 2020, 11, 641.	2.6	30
25	Visual stimuli induce serotonin release in occipital cortex: A simultaneous positron emission tomography/magnetic resonance imaging study. Human Brain Mapping, 2020, 41, 4753-4763.	3.6	7
26	Small sample corrections for Wald tests in latent variable models. Journal of the Royal Statistical Society Series C: Applied Statistics, 2020, 69, 841-861.	1.0	5
27	Psychometric Properties of the Verbal Affective Memory Test-26 and Evaluation of Affective Biases in Major Depressive Disorder. Frontiers in Psychology, 2020, 11, 961.	2.1	6
28	A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology, 2020, 33, 71-80.	0.7	88
29	Severity of self-reported depressive symptoms in a healthy sample is modulated by trait Harm Avoidance, not by 5-HTTLPR polymorphism. Psychiatry Research, 2020, 291, 113029.	3.3	1
30	On the estimation of average treatment effects with rightâ€eensored time to event outcome and competing risks. Biometrical Journal, 2020, 62, 751-763.	1.0	42
31	Evaluation of inferential methods for the net benefit and win ratio statistics. Journal of Biopharmaceutical Statistics, 2020, 30, 765-782.	0.8	20
32	Comparison of classification methods for tissue outcome after ischaemic stroke. European Journal of Neuroscience, 2019, 50, 3590-3598.	2.6	5
33	Individualized quantification of the benefit from reperfusion therapy using stroke predictive models. European Journal of Neuroscience, 2019, 50, 3251-3260.	2.6	0
34	Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology, 2019, 44, 1328-1334.	5.4	259
35	Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit. Journal of the National Cancer Institute, 2019, 111, 1186-1191.	6.3	13
36	Preprocessing, Prediction and Significance: Framework and Application to Brain Imaging. Lecture Notes in Computer Science, 2019, , 196-204.	1.3	1

#	Article	IF	CITATIONS
37	Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study. European Heart Journal, 2018, 39, 1698-1705a.	2.2	28
38	Self-perceived personality characteristics in seasonal affective disorder and their implications for severity of depression. Psychiatry Research, 2018, 262, 108-114.	3.3	4
39	Amygdala response to emotional faces in seasonal affective disorder. Journal of Affective Disorders, 2018, 229, 288-295.	4.1	8
40	Verbal learning and memory outcome in selective amygdalohippocampectomy versus temporal lobe resection in patients with hippocampal sclerosis. Epilepsy and Behavior, 2018, 79, 180-187.	1.7	14
41	An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. Statistical Methods in Medical Research, 2018, 27, 1230-1239.	1.5	43
42	Pre-intervention test-retest reliability of EEG and ERP over four recording intervals. International Journal of Psychophysiology, 2018, 134, 30-43.	1.0	37
43	Brain serotonin 4 receptor binding is inversely associated withÂverbal memory recall. Brain and Behavior, 2017, 7, e00674.	2.2	13
44	A High-Resolution <i>In Vivo</i> Atlas of the Human Brain's Serotonin System. Journal of Neuroscience, 2017, 37, 120-128.	3.6	8
45	Season-independent cognitive deficits in seasonal affective disorder and their relation to depressive symptoms. Psychiatry Research, 2017, 257, 219-226.	3.3	12
46	A High-Resolution <i>In Vivo </i> Atlas of the Human Brain's Serotonin System. Journal of Neuroscience, 2017, 37, 120-128.	3.6	262
47	Safety and EEG data quality of concurrent high-density EEG and high-speed fMRI at 3 Tesla. PLoS ONE, 2017, 12, e0178409.	2.5	18
48	riskRegression: Predicting the Risk of an Event using Cox Regression Models. R Journal, 2017, 9, 440.	1.8	64
49	The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. JAMA Oncology, 2016, 2, 901.	7.1	47
50	Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. European Heart Journal, 2016, 38, ehw496.	2.2	74
51	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 2016, 7, 82953-82960.	1.8	22
52	Evaluation of Early Reperfusion Criteria in Acute Ischemic Stroke. Journal of Neuroimaging, 2015, 25, 952-958.	2.0	2
53	Spatially regularized mixture model for lesion segmentation with application to stroke patients. Biostatistics, 2015, 16, 580-595.	1.5	7
54	The precision–recall curve overcame the optimism of the receiver operating characteristic curve in rare diseases. Journal of Clinical Epidemiology, 2015, 68, 855-859.	5.0	209

#	Article	IF	CITATION
55	Very Low Cerebral Blood Volume Predicts Parenchymal Hematoma in Acute Ischemic Stroke. Stroke, 2013, 44, 2318-2320.	2.0	33
56	Brain serotonin transporter is associated with cognitiveâ€affective biases in healthy individuals. Human Brain Mapping, 0, , .	3.6	3